$4.16
0.122.97%
At Close: -
$4.22
0.061.44%
After Hours: 7:35 PM EDT
15 minutes delayed
Comments
Loading...
Adaptive Biotechnologies
ADPTNASDAQ
Adaptive Biotechnologies (NASDAQ:ADPT) Stock, Analyst Ratings, Price Targets, Forecasts
Adaptive Biotechnologies Corp has a consensus price target of $13.13 based on the ratings of 8 analysts. The high is $52 issued by Goldman Sachs on August 6, 2021. The low is $5 issued by JP Morgan on May 8, 2024. The 3 most-recent analyst ratings were released by JP Morgan, BTIG, and Goldman Sachs on May 8, 2024, April 4, 2024, and February 16, 2024, respectively. With an average price target of $5 between JP Morgan, BTIG, and Goldman Sachs, there's an implied 18.49% upside for Adaptive Biotechnologies Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
BTIG
Goldman Sachs
Piper Sandler
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for Adaptive Biotechnologies
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/08/2024 | Buy Now | 18.49% | JP Morgan | Rachel Vatnsdal | $8 → $5 | Maintains | Overweight | Get Alert |
| 04/04/2024 | Buy Now | 18.49% | BTIG | Mark Massaro | $6 → $5 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | 18.49% | Goldman Sachs | Salveen Richter | $11 → $5 | Maintains | Neutral | Get Alert |
| 02/15/2024 | Buy Now | 89.58% | JP Morgan | Rachel Vatnsdal | $11 → $8 | Maintains | Overweight | Get Alert |
| 11/13/2023 | Buy Now | 42.18% | Piper Sandler | David Westenberg | $13 → $6 | Maintains | Overweight | Get Alert |
| 11/10/2023 | Buy Now | 160.67% | JP Morgan | Rachel Vatnsdal | $12 → $11 | Maintains | Overweight | Get Alert |
| 10/24/2023 | Buy Now | 136.97% | Morgan Stanley | Tejas Savant | $13 → $10 | Maintains | Equal-Weight | Get Alert |
| 10/16/2023 | Buy Now | 208.06% | Piper Sandler | David Westenberg | $14 → $13 | Maintains | Overweight | Get Alert |
| 08/08/2023 | Buy Now | 231.76% | Piper Sandler | David Westenberg | $15 → $14 | Maintains | Overweight | Get Alert |
| 08/04/2023 | Buy Now | 208.06% | Morgan Stanley | Tejas Savant | $14 → $13 | Maintains | Equal-Weight | Get Alert |
| 05/05/2023 | Buy Now | 231.76% | Morgan Stanley | Tejas Savant | $15 → $14 | Maintains | Equal-Weight | Get Alert |
| 02/16/2023 | Buy Now | 255.46% | Morgan Stanley | Tejas Savant | $16 → $15 | Maintains | Equal-Weight | Get Alert |
| 02/15/2023 | Buy Now | 65.88% | Credit Suisse | Dan Leonard | → $7 | Reiterates | → Underperform | Get Alert |
| 01/05/2023 | Buy Now | 255.46% | Scotiabank | Sung Ji Nam | → $15 | Initiates | → Sector Outperform | Get Alert |
| 12/21/2022 | Buy Now | 231.76% | Piper Sandler | David Westenberg | $7.5 → $14 | Upgrade | Neutral → Overweight | Get Alert |
| 11/07/2022 | Buy Now | 279.16% | Morgan Stanley | Tejas Savant | $17 → $16 | Maintains | Equal-Weight | Get Alert |
| 10/26/2022 | Buy Now | 77.73% | Piper Sandler | David Westenberg | $12 → $7.5 | Maintains | Neutral | Get Alert |
| 08/25/2022 | Buy Now | 89.58% | Credit Suisse | Dan Leonard | → $8 | Initiates | → Underperform | Get Alert |
| 08/17/2022 | Buy Now | 184.37% | Piper Sandler | David Westenberg | $7.5 → $12 | Maintains | Neutral | Get Alert |
| 06/03/2022 | Buy Now | 77.73% | Piper Sandler | David Westenberg | → $7.5 | Initiates | → Neutral | Get Alert |
| 05/24/2022 | Buy Now | 136.97% | Goldman Sachs | Salveen Richter | $14 → $10 | Maintains | Neutral | Get Alert |
| 05/06/2022 | Buy Now | 326.55% | Morgan Stanley | Tejas Savant | $27 → $18 | Maintains | Equal-Weight | Get Alert |
| 02/16/2022 | Buy Now | 610.92% | BTIG | Mark Massaro | $35 → $30 | Maintains | Buy | Get Alert |
| 02/15/2022 | Buy Now | 539.83% | Morgan Stanley | Tejas Savant | $46 → $27 | Maintains | Equal-Weight | Get Alert |
| 08/06/2021 | Buy Now | 1132.26% | Goldman Sachs | — | — | Maintains | Neutral | Get Alert |
FAQ
What is the target price for Adaptive Biotechnologies (ADPT) stock?
The latest price target for Adaptive Biotechnologies (NASDAQ:ADPT) was reported by JP Morgan on May 8, 2024. The analyst firm set a price target for $5.00 expecting ADPT to rise to within 12 months (a possible 18.49% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Adaptive Biotechnologies (ADPT)?
The latest analyst rating for Adaptive Biotechnologies (NASDAQ:ADPT) was provided by JP Morgan, and Adaptive Biotechnologies maintained their overweight rating.
When was the last upgrade for Adaptive Biotechnologies (ADPT)?
The last upgrade for Adaptive Biotechnologies Corp happened on December 21, 2022 when Piper Sandler raised their price target to $14. Piper Sandler previously had a neutral for Adaptive Biotechnologies Corp.
When was the last downgrade for Adaptive Biotechnologies (ADPT)?
There is no last downgrade for Adaptive Biotechnologies.
When is the next analyst rating going to be posted or updated for Adaptive Biotechnologies (ADPT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adaptive Biotechnologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adaptive Biotechnologies was filed on May 8, 2024 so you should expect the next rating to be made available sometime around May 8, 2025.
Is the Analyst Rating Adaptive Biotechnologies (ADPT) correct?
While ratings are subjective and will change, the latest Adaptive Biotechnologies (ADPT) rating was a maintained with a price target of $8.00 to $5.00. The current price Adaptive Biotechnologies (ADPT) is trading at is $4.22, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.